Prognostic signatures of specific immune-related long noncoding RNAs (irlncRNAs) have been elucidated with the development of immunotherapy for breast cancer, but the heterogeneity of gene expression in different patients still limits their effectiveness. We constructed a new prognostic signature based on the relative expression of differentially expressed irlncRNA (DEirlncRNA) pairs and analyzed its clinical application in 1069 patients from The Cancer Genome Atlas-Breast Cancer (TCGA-BRCA) containing 745 White patients, 180 Black and African American patients, 58 Asian patients, 181 stage I patients, 606 stage II patients, 240 stage III patients, and 20 stage IV patients. Data from TCGA-BRCA and ImmPort were used to screen DEirlncRNAs, and the DEirlncRNA pairs were established by cyclical single comparison of each DEirlncRNA. After the data optimization, we constructed a signature containing 24 DEirlncRNA pairs. Risk groups of this signature were defined using the cutoff value from the 10-year survival receiver operating characteristic curve, and Kaplan–Meier analysis verified its prognostic effectiveness. Furthermore, we confirmed this signature as an independent prognostic factor and confirmed its close association with traditional clinicopathological factors. Moreover, this risk signature was closely related to tumor-infiltrating immune cells and drug susceptibility. In short, we successfully constructed a risk signature of DEirlncRNA pairs, which might provide new insights for breast cancer precision therapy.
Get full access to this article
View all access options for this article.
References
1.
AmaralP.P., LeonardiT., HanN., VireE., GascoigneD.K., Arias-CarrascoR., et al. (2018). Genomic positional conservation identifies topological anchor point RNAs linked to developmental loci. Genome Biol, 19, 32.
2.
AranD., HuZ., and ButteA.J. (2017). xCell: digitally portraying the tissue cellular heterogeneity landscape. Genome Biol, 18, 220.
3.
BaldT., KrummelM.F., SmythM.J., and BarryK.C. (2020). The NK cell-cancer cycle: advances and new challenges in NK cell-based immunotherapies. Nat Immunol, 21, 835–847.
4.
ChenB., KhodadoustM.S., LiuC.L., NewmanA.M., and AlizadehA.A. (2018). Profiling tumor infiltrating immune cells with CIBERSORT. Methods Mol Biol, 1711, 243–259.
5.
ChoiS.H., ChangJ.S., KooJ.S., ParkJ.W., SohnJ.H., KeumK.C., et al. (2018). Differential prognostic impact of strong PD-L1 expression and 18F-FDG uptake in triple-negative breast cancer. Am J Clin Oncol, 41, 1049–1057.
6.
DongH., HuJ., ZouK., YeM., ChenY., WuC., et al. (2019). Activation of LncRNA TINCR by H3K27 acetylation promotes Trastuzumab resistance and epithelial-mesenchymal transition by targeting MicroRNA-125b in breast Cancer. Mol Cancer, 18, 3.
7.
EmensL.A. (2018). Breast cancer immunotherapy: facts and hopes. Clin Cancer Res, 24, 511–520.
8.
Flores-ConchaM., and OnateA.A. (2020). Long non-coding RNAs in the regulation of the immune response and trained immunity. Front Genet, 11, 718.
9.
GuG., DustinD., and FuquaS.A. (2016). Targeted therapy for breast cancer and molecular mechanisms of resistance to treatment. Curr Opin Pharmacol, 31, 97–103.
10.
HammerlD., SmidM., TimmermansA.M., SleijferS., MartensJ.W.M., and DebetsR. (2018). Breast cancer genomics and immuno-oncological markers to guide immune therapies. Semin Cancer Biol, 52, 178–188.
11.
HanC., LiX., FanQ., LiuG., and YinJ. (2019). CCAT1 promotes triple-negative breast cancer progression by suppressing miR-218/ZFX signaling. Aging (Albany NY), 11, 4858–4875.
12.
HanzelmannS., CasteloR., and GuinneyJ. (2013). GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics, 14, 7.
13.
HauptmanN., and GlavacD. (2013). MicroRNAs and long non-coding RNAs: prospects in diagnostics and therapy of cancer. Radiol Oncol, 47, 311–318.
14.
HendersonI.C., BerryD.A., DemetriG.D., CirrincioneC.T., GoldsteinL.J., MartinoS., et al. (2003). Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol, 21, 976–983.
15.
KhanM.A., JainV.K., RizwanullahM., AhmadJ., and JainK. (2019). PI3K/AKT/mTOR pathway inhibitors in triple-negative breast cancer: a review on drug discovery and future challenges. Drug Discov Today, 24, 2181–2191.
16.
KimJ., PiaoH.L., KimB.J., YaoF., HanZ., WangY., et al. (2018). Long noncoding RNA MALAT1 suppresses breast cancer metastasis. Nat Genet, 50, 1705–1715.
17.
KotsopoulosJ. (2018). BRCA mutations and breast cancer prevention. Cancers (Basel), 10, 524.
18.
LaiJ., ChenB., ZhangG., LiX., MokH., and LiaoN. (2020). Molecular characterization of breast cancer: a potential novel immune-related lncRNAs signature. J Transl Med, 18, 416.
19.
LiT., FanJ., WangB., TraughN., ChenQ., LiuJ.S., et al. (2017). TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res, 77, e108–e110.
20.
LiT., FuJ., ZengZ., CohenD., LiJ., ChenQ., et al. (2020a). TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res, 48, W509–W514.
21.
LiX., DengS., PangX., SongY., LuoS., JinL., et al. (2019). LncRNA NEAT1 silenced miR-133b promotes migration and invasion of breast cancer cells. Int J Mol Sci, 20, 3616.
22.
LiZ., LiY., WangX., and YangQ. (2020b). Identification of a six-immune-related long non-coding RNA signature for predicting survival and immune infiltrating status in breast cancer. Front Genet, 11, 680.
23.
LiuZ., MiM., LiX., ZhengX., WuG., and ZhangL. (2020). A lncRNA prognostic signature associated with immune infiltration and tumour mutation burden in breast cancer. J Cell Mol Med, 24, 12444–12456.
24.
MaW., ZhaoF., YuX., GuanS., SuoH., TaoZ., et al. (2020). Immune-related lncRNAs as predictors of survival in breast cancer: a prognostic signature. J Transl Med, 18, 442.
25.
MamounasE.P., BryantJ., LemberskyB., FehrenbacherL., SedlacekS.M., FisherB., et al. (2005). Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol, 23, 3686–3696.
26.
Martins-TeixeiraM.B., and CarvalhoI. (2020). Antitumour anthracyclines: progress and perspectives. ChemMedChem, 15, 933–948.
27.
PlattnerC., FinotelloF., and RiederD. (2020). Deconvoluting tumor-infiltrating immune cells from RNA-seq data using quanTIseq. Method Enzymol, 636, 261–285.
28.
RuffellB., and CoussensL.M. (2015). Macrophages and therapeutic resistance in cancer. Cancer Cell, 27, 462–472.
29.
SchmidP. (2018). ESMO 2018 presidential symposium-IMpassion130: atezolizumab+nab-paclitaxel in triple-negative breast cancer. ESMO Open, 3, e000453.
30.
SchmidP., CortesJ., PusztaiL., McArthurH., KummelS., BerghJ., et al. (2020). Pembrolizumab for early triple-negative breast cancer. N Engl J Med, 382, 810–821.
31.
SchmittA.M., and ChangH.Y. (2016). Long noncoding RNAs in cancer pathways. Cancer Cell, 29, 452–463.
32.
ShenY., PengX., and ShenC. (2020). Identification and validation of immune-related lncRNA prognostic signature for breast cancer. Genomics, 112, 2640–2646.
33.
SiegelR.L., MillerK.D., FuchsH.E., and JemalA. (2021). Cancer statistics, 2021. CA Cancer J Clin, 71, 7–33.
34.
SobczukP., CzerwinskaM., KleibertM., and Cudnoch-JedrzejewskaA. (2020). Anthracycline-induced cardiotoxicity and renin-angiotensin-aldosterone system-from molecular mechanisms to therapeutic applications. Heart Fail Rev [Epub ahead of print]; DOI: 10.1007/s10741-020-09977-1.
35.
SunX., HuangT., LiuZ., SunM., and LuoS. (2019). LncRNA SNHG7 contributes to tumorigenesis and progression in breast cancer by interacting with miR-34a through EMT initiation and the Notch-1 pathway. Eur J Pharmacol, 856, 172407.
36.
SungH., FerlayJ., SiegelR.L., LaversanneM., SoerjomataramI., JemalA., et al. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 71, 209–249.
37.
TokunagaR., NaseemM., LoJ.H., BattaglinF., SoniS., PucciniA., et al. (2019). B cell and B cell-related pathways for novel cancer treatments. Cancer Treat Rev, 73, 10–19.
38.
TrailP.A., DubowchikG.M., and LowingerT.B. (2018). Antibody drug conjugates for treatment of breast cancer: novel targets and diverse approaches in ADC design. Pharmacol Ther, 181, 126–142.
39.
van der LeunA.M., ThommenD.S., and SchumacherT.N. (2020). CD8(+) T cell states in human cancer: insights from single-cell analysis. Nat Rev Cancer, 20, 218–232.
40.
WangJ., XieS., YangJ., XiongH., JiaY., ZhouY., et al. (2019a). The long noncoding RNA H19 promotes tamoxifen resistance in breast cancer via autophagy. J Hematol Oncol, 12, 81.
41.
WangY.Y., YanL., YangS., XuH.N., ChenT.T., DongZ.Y., et al. (2019b). Long noncoding RNA AC073284.4 suppresses epithelial-mesenchymal transition by sponging miR-18b-5p in paclitaxel-resistant breast cancer cells. J Cell Physiol, 234, 23202–23215.
42.
WeberR., FlemingV., HuX., NagibinV., GrothC., AltevogtP., et al. (2018). Myeloid-derived suppressor cells hinder the anti-cancer activity of immune checkpoint inhibitors. Front Immunol, 9, 1310.
43.
ZengY., WangG., ZhouC.F., ZhangH.B., SunH., ZhangW., et al. (2019). LncRNA profile study reveals a three-lncRNA signature associated with the pathological complete response following neoadjuvant chemotherapy in breast cancer. Front Pharmacol, 10, 574.
44.
ZhengA., SongX., ZhangL., ZhaoL., MaoX., WeiM., et al. (2019) Long non-coding RNA LUCAT1/miR-5582-3p/TCF7L2 axis regulates breast cancer stemness via Wnt/beta-catenin pathway. J Exp Clin Cancer Res, 38, 305.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
